Ginkgo Bioworks Holdings Inc (NYSE: DNA) kicked off on Monday, down -5.13% from the previous trading day, before settling in for the closing price of $5.65. Over the past 52 weeks, DNA has traded in a range of $5.64-$87.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 104.75% over the last five years. While this was happening, its average annual earnings per share was recorded 43.06%. With a float of $35.47 million, this company’s outstanding shares have now reached $38.13 million.
The firm has a total of 1218 workers. Let’s measure their productivity. In terms of profitability, gross margin is 58.77%, operating margin of -406.93%, and the pretax margin is -486.98%.
Ginkgo Bioworks Holdings Inc (DNA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.54%, while institutional ownership is 44.82%. The most recent insider transaction that took place on Sep 09 ’24, was worth 563. Before that another transaction happened on Sep 06 ’24, when Company’s Officer proposed sale 99 for $6.06, making the entire transaction worth $600.
Ginkgo Bioworks Holdings Inc (DNA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -6.4 earnings per share (EPS), lower than consensus estimate (set at -3.43) by -2.97. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.06% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Take a look at Ginkgo Bioworks Holdings Inc’s (DNA) current performance indicators. Last quarter, stock had a quick ratio of 4.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -18.03, a number that is poised to hit -2.74 in the next quarter and is forecasted to reach -7.45 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Analysing the last 5-days average volume posted by the [Ginkgo Bioworks Holdings Inc, DNA], we can find that recorded value of 1.74 million was better than the volume posted last year of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 2.68%. Additionally, its Average True Range was 1.05.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 0.18%, which indicates a significant decrease from 1.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.49% in the past 14 days, which was higher than the 117.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.91, while its 200-day Moving Average is $36.02. Now, the first resistance to watch is $5.62. This is followed by the second major resistance level at $5.89. The third major resistance level sits at $6.05. If the price goes on to break the first support level at $5.19, it is likely to go to the next support level at $5.03. Now, if the price goes above the second support level, the third support stands at $4.76.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
The company with the Market Capitalisation of 281.83 million has total of 2,211,278K Shares Outstanding. Its annual sales at the moment are 251,460 K in contrast with the sum of -892,870 K annual income. Company’s last quarter sales were recorded 56,210 K and last quarter income was -217,180 K.
